NASDAQ:TRVN Trevena Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.39 -0.02 (-4.88%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$0.38▼$0.4250-Day Range$0.20▼$0.4652-Week Range$0.18▼$1.72Volume1.25 million shsAverage Volume1.51 million shsMarket Capitalization$64.55 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Trevena Stock Forecast (MarketRank)Analyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,117.9% Upside$4.75 Price TargetShort InterestHealthy11.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 4 Articles This WeekInsider TradingSelling Shares$13.03 K Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.37) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.67 out of 5 starsMedical Sector660th out of 1,429 stocksPharmaceutical Preparations Industry311th out of 682 stocks 3.3 Analyst's Opinion Consensus RatingTrevena has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.75, Trevena has a forecasted upside of 1,117.9% from its current price of $0.39.Amount of Analyst CoverageTrevena has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.17% of the float of Trevena has been sold short.Short Interest Ratio / Days to CoverTrevena has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevena has recently decreased by 3.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTrevena does not currently pay a dividend.Dividend GrowthTrevena does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVN. Previous Next 2.5 News and Social Media Coverage News SentimentTrevena has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Trevena this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for TRVN on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat Follows6 people have added Trevena to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,032.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Trevena is held by insiders.Percentage Held by InstitutionsOnly 21.20% of the stock of Trevena is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trevena are expected to grow in the coming year, from ($0.37) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevena is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevena is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevena has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Email Address About Trevena (NASDAQ:TRVN)Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.Read More TRVN Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comBarry Shin Sells 31,785 Shares of Trevena, Inc. (NASDAQ:TRVN) StockJune 25, 2022 | americanbankingnews.comTrevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.comJune 17, 2022 | americanbankingnews.comTrevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.comJune 16, 2022 | benzinga.comTrevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operati - BenzingaJune 14, 2022 | finance.yahoo.comTrevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative CareJune 10, 2022 | globenewswire.comTrevena to Participate at the JMP Securities Life Sciences Conference - GlobeNewswireJune 10, 2022 | finance.yahoo.comTrevena to Participate at the JMP Securities Life Sciences ConferenceJune 10, 2022 | americanbankingnews.comTrevena, Inc. (NASDAQ:TRVN) to Post FY2023 Earnings of ($0.37) Per Share, Cantor Fitzgerald ForecastsJune 8, 2022 | americanbankingnews.comTrevena (NASDAQ:TRVN) Research Coverage Started at StockNews.comJune 2, 2022 | streetinsider.comHot Penny Stocks Under $1 To Watch In June - StreetInsider.comMay 18, 2022 | finance.yahoo.comTrevena to Present at the H.C. Wainwright Global Investment ConferenceMay 13, 2022 | seekingalpha.comTrevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2022 Results - Earnings Call Transcript - Seeking AlphaMay 12, 2022 | benzinga.comHC Wainwright & Co. Maintains Buy on Trevena, Lowers Price Target to $3.5 - Benzinga - BenzingaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVN CUSIPN/A CIK1429560 Webwww.trevena.com Phone(610) 354-8840FaxN/AEmployees25Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today7/01/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$4.75 High Stock Price Forecast$6.00 Low Stock Price Forecast$3.50 Forecasted Upside/Downside+1,117.9%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51.59 million Net Margins-7,771.74% Pretax Margin-15,379.63% Return on Equity-82.39% Return on Assets-66.75% Debt Debt-to-Equity RatioN/A Current Ratio6.08 Quick Ratio5.77 Sales & Book Value Annual Sales$570 thousand Price / Sales113.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book1.00Miscellaneous Outstanding Shares165,520,000Free Float159,561,000Market Cap$64.55 million OptionableOptionable Beta2.44 Trevena Frequently Asked Questions Should I buy or sell Trevena stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Trevena stock. View analyst ratings for Trevena or view top-rated stocks. What is Trevena's stock price forecast for 2022? 2 brokerages have issued 1 year price targets for Trevena's shares. Their TRVN stock forecasts range from $3.50 to $6.00. On average, they predict Trevena's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 1,117.9% from the stock's current price. View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts. How has Trevena's stock performed in 2022? Trevena's stock was trading at $0.5830 at the beginning of 2022. Since then, TRVN stock has decreased by 33.1% and is now trading at $0.39. View the best growth stocks for 2022 here. When is Trevena's next earnings date? Trevena is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Trevena. How were Trevena's earnings last quarter? Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Wednesday, May, 11th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.65 million. Trevena had a negative trailing twelve-month return on equity of 82.39% and a negative net margin of 7,771.74%. During the same period in the previous year, the firm posted ($0.06) earnings per share. View Trevena's earnings history. Who are Trevena's key executives? Trevena's management team includes the following people: Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 59, Pay $920.39k) (LinkedIn Profile)Mr. Barry Shin, Sr. VP & CFO (Age 50, Pay $609.94k)Dr. Mark A. Demitrack, Sr. VP & Chief Medical Officer (Age 64, Pay $641.3k)Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory BoardMr. Joel Solomon, VP, Head of Legal, Chief Compliance Officer & Corp. Sec.Mr. Michael Catalano, VP of MarketingMr. Robert T. Yoder, Sr. VP, Chief Bus. Officer & Head of Commercial Operations (Age 56)Ms. Patricia M. Drake, Sr. VP & Chief Commercial Officer (Age 56) Who are some of Trevena's key competitors? Some companies that are related to Trevena include Exicure (XCUR), Prelude Therapeutics (PRLD), InterCure (INCR), Thorne HealthTech (THRN), LianBio (LIAN), Sernova (SEOVF), Epizyme (EPZM), KalVista Pharmaceuticals (KALV), Rallybio (RLYB), PepGen (PEPG), XOMA (XOMA), Inventiva (IVA), CymaBay Therapeutics (CBAY), AVEO Pharmaceuticals (AVEO) and Aldeyra Therapeutics (ALDX). View all of TRVN's competitors. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX). What is Trevena's stock symbol? Trevena trades on the NASDAQ under the ticker symbol "TRVN." How do I buy shares of Trevena? Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Trevena's stock price today? One share of TRVN stock can currently be purchased for approximately $0.39. How much money does Trevena make? Trevena (NASDAQ:TRVN) has a market capitalization of $64.55 million and generates $570 thousand in revenue each year. The biopharmaceutical company earns $-51.59 million in net income (profit) each year or ($0.35) on an earnings per share basis. How many employees does Trevena have? Trevena employs 25 workers across the globe. How can I contact Trevena? Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for Trevena is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected]. This page (NASDAQ:TRVN) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
